Preview

Влияние субклинического тиреотоксикоза на сердечно-сосудистую систему

https://doi.org/10.14341/ket2015233-37

Полный текст:

Аннотация

ГБОУ ДПО “Российская медицинская академия последипломного образования” Минздрава России, Москва Субклинический тиреотоксикоз характеризуется сниженным или неопределяемым уровнем тиреотропного гормона в сочетании с нормальными уровнями тироксина и трийодтиронина. Клинические проявления субклинического тиреотоксикоза являются малоизученными. Субклинический тиреотоксикоз оказывает несколько эффектов на сердечно-сосудистую систему, например, увеличение частоты сердечных сокращений, массы левого желудочка. Экспериментальные исследования выявили связь между субклиническим тиреотоксикозом и ишемической болезнью сердца, частотой возникновения фибрилляции предсердий и сердечной дисфункции.

Об авторах

Татьяна Юльевна Демидова
ГБОУ ДПО “Российская медицинская академия последипломного образования” Минздрава России, Москва
д.м.н., профессор кафедры эндокринологии и диабетологии ГБОУ ДПО РМАПО Минздрава России, Москва.


Ирина Николаевна Дроздова
ГБОУ ДПО “Российская медицинская академия последипломного образования” Минздрава России, Москва
аспирант кафедры эндокринологии и диабетологии ГБОУ ДПО РМАПО Минздрава России, Москва.


Список литературы

1. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid Disease Prevalence Study. Arch. Intern. Med. 2000; 160(4):526. doi: 10.1001/archinte.160.4.526.

2. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J ClinEndocrinol Metab. 2002;87(2):489-499. doi: 10.1210/jcem.87.2.8182

3. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249-1252. doi: 10.1056/nejm199411103311901.

4. Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Endocr Pract. 2004;10(6):497-501. doi: 10.4158/ep.10.6.497.

5. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease. JAMA. 2004;291(2):228. doi: 10.1001/jama.291.2.228.

6. Wilson GR, Curry RW. Subclinical thyroid disease. Amer Fam Physician. 2005;72(8):1517-1524.

7. Дедов И.И., Мельниченко Г.А. Болезнь Грейвса и эндокринная офтальмопатия. - М.; 2012. [Dedov II, Mel’nichenko GA. Bolezn’ Greivsa i endokrinnaya oftal’mopatiya. Moscow; 2012. (In Russ).]

8. Cooper DS. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2007;92(1):3-9. doi: 10.1210/jc.2006-2472.

9. Biondi B, Palmieri EA, Klain M, et al. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol / European Federation of Endocrine Societies. 2005;152(1):1-9. doi: 10.1530/eje.1.01809.

10. Ross DS. Subclinical thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott, Williams and Wilkins; 2000; 1016-1020.

11. Papi G, Pearce EN, Braverman LE, et al. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. Am J Med. 2005;118(4):349-361. doi: 10.1016/j.amjmed.2005.01.004.

12. Cooper DS. Hyperthyroidism. The Lancet. 2003;362(9382):459-468. doi: 10.1016/s0140-6736(03)14073-1.

13. Toft AD. Subclinical hyperthyroidism. N Engl J Med. 2001;345(7): 512-516. doi: 10.1056/NEJMcp010145.

14. Boelaert K. Thyroid hormone in health and disease. J Endocrinol. 2005;187(1):1-15. doi: 10.1677/joe.1.06131.

15. Brownlie BEW, Legge HM. Thyrotropin results in euthyroid patients with a past history of hyperthyroidism. Eur J Endocrinol / European Federation of Endocrine Societies. 1990;122(5):623-627. doi: 10.1530/acta.0.1220623.

16. Charkes ND. The many causes of subclinical hyperthyroidism. Thyroid. 1996;6(5):391-396. doi: 10.1089/thy.1996.6.391.

17. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol / European Federation of Endocrine Societies. 1994;130(4):350-356. doi: 10.1530/eje.0.1300350.

18. Marqusee E, Haden ST, Utiger RD. Subclinical thyrotoxicosis. Endocrinol Metab Clin N Am. 1998;27(1):37-49. doi: 10.1016/s0889-8529(05)70296-6.

19. Sawin CT. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med. 1991;151(1):165. doi: 10.1001/archinte.1991.00400010159025.

20. Cooper DS. Subclinical thyroid disease: A clinician’s perspective. Ann Intern Med. 1998;129(2):135. doi: 10.7326/0003-4819-129-2-199807150-00016.

21. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85(12):4701-4705. doi: 10.1210/jcem.85.12.7085.

22. Sgarbi JA, Villaça FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab. 2003;88(4):1672-1677. doi: 10.1210/jc.2002-021046.

23. Pearce EN, Yang Q, Benjamin EJ, et al. Thyroid function and left ventricular structure and function in the Framingham Heart Study. Thyroid. 2010;20(4):369-373. doi: 10.1089/thy.2009.0272.

24. Dörr M, Ittermann T, Aumann N, et al. Subclinical hyperthyroidism is not associated with progression of cardiac mass and development of left ventricular hypertrophy in middle-aged and older subjects: results from a 5-year follow-up. Clin Endocrinol (Oxf). 2010;73(6):821-826. doi: 10.1111/j.1365-2265.2010.03882.x.

25. Petretta M, Bonaduce D, Spinelli L, et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol / European Federation of Endocrine Societies. 2001;145(6):691-696. doi: 10.1530/eje.0.1450691.

26. Yavuz H, Altunbag H, Balci M, et al. Normal systolic time intervals in subclinical hyperthyroidism. J Endocrinol Invest. 2000; 23(7; SUPP 1):38-38.

27. Psaltopoulou T, Ilias I, Toumanidis S, et al. Endogenous subclinical hyperthyroidism: Metabolic and cardiac parameters. Eur J Intern Med. 2007;18(5):423-429. doi: 10.1016/j.ejim.2006.12.010.

28. Leese GP, Jung RT, Guthrie C, et al. Morbidity in patients on l-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf). 1992;37(6):500-503. doi: 10.1111/j.1365-2265.1992.tb01480.x.

29. Dorr M, Robinson DM, Wallaschofski H, et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab. 2006;91(2):530-534. doi: 10.1210/jc.2005-1786.

30. Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf). 2006;64(3): 323-329. doi: 10.1111/j.1365-2265.2006.02464.x.

31. Franchini M, Lippi G, Targher G. Hyperthyroidism and venous thrombosis: A casual or causal association? A systematic literature review. Clin Appl Thromb Hemost. 2010;17(4):387-392. doi: 10.1177/1076029610364521.

32. Volzke H, Robinson DM, Schminke U, et al. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab. 2004;89(5): 2145-2149. doi: 10.1210/jc.2003-031028.

33. Dorr M, Empen K, Robinson DM, et al. The association of thyroid function with carotid artery plaque burden and strokes in a population-based sample from a previously iodine-deficient area. Eur J Endocrinol. 2008;159(2):145-152. doi: 10.1530/EJE-08-0140.

34. Tenerz Å, Forberg R, Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J Intern Med. 2009;228(3):229-233. doi: 10.1111/j.1365-2796.1990.tb00223.x.

35. Machill K, Scholz GH. Dependence of haemodynamic changes in hypothyroidism on age of patients and etiology hyperthyroidism. In: Braverman E, Eber O, Langsteger W, editors. Heart and thyroid. Wien; 1994. p. 203.

36. Polikar R, Feld GK, Dittrich HC, et al. Effect of thyroid replacement therapy on the frequency of benign atrial and ventricular arrhythmias. J Am Coll Cardiol. 1989;14(4):999-1002. doi: 10.1016/0735-1097(89)90479-8.

37. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142(5): 838-842. doi: 10.1067/mhj.2001.119370.

38. Gammage MD. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167(9):928. doi: 10.1001/archinte.167.9.928.

39. Surks MI, Goswami G, Daniels GH. The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab. 2005;90(9):5489-5496. doi: 10.1210/jc.2005-0170.

40. Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. The Lancet. 2001;358(9285):861-865. doi: 10.1016/s0140-6736(01)06067-6.


Для цитирования:


Демидова Т.Ю., Дроздова И.Н. Влияние субклинического тиреотоксикоза на сердечно-сосудистую систему. Клиническая и экспериментальная тиреоидология. 2015;11(2):33-37. https://doi.org/10.14341/ket2015233-37

For citation:


Demidova T.Y., Drozdova I.N. Influence of subclinical hyperthyroidism on the cardiovascular system. Clinical and experimental thyroidology. 2015;11(2):33-37. (In Russ.) https://doi.org/10.14341/ket2015233-37

Просмотров: 4


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-5472 (Print)
ISSN 2310-3787 (Online)